Karyopharm Therapeutics Announces Advance of Neuroprotective SINE(TM) Compounds for …

You may also like…. Kadimastem To Initiate a Human Clinical Trial for Promising ALS Therapy ALS Association Meeting Presents Data on Research Achievements at Recent AAN Meeting Cell Metabolite Reduces Neuronal Death in ALS, Study Shows Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs for the treatment of cancer and other major diseases, recently announced the evaluation of its SINE nuclear transport compound KPT-350 as a treatment for Amyotrophic Lateral Sclerosis (ALS). Results from preclinical studies will be presented during upcoming neuroscience conferences. In a recent study published in Nature, the nuclear transport was found to disrupt a mutation present in patients with ALS.  Results from the study showed that C9orf72, the most usual cause of familial and sporadic Frontotemporal Degeneration and ALS, caused complications with…


Link to Full Article: Karyopharm Therapeutics Announces Advance of Neuroprotective SINE(TM) Compounds for …